Obesity and low testosterone have a bidirectional relationship that makes each one worse: excess body fat contains an enzyme called aromatase that converts testosterone into estradiol, which drives testosterone levels down further, which makes it easier to gain more fat. Breaking that loop with a single treatment is possible, but a growing number of telehealth platforms now treat both sides at once — TRT to restore the hormonal baseline, a GLP-1 to address the metabolic side.
Here's what the research actually supports, and what monitoring looks like if you're considering both.
What the evidence shows
Data presented at the 2025 Endocrine Society annual meeting found that men with obesity or type 2 diabetes taking GLP-1 medications saw meaningful improvement in both directions: after roughly 18 months, participants lost about 10% of body weight, and their average total testosterone rose by 18%. A separate clinical trial found men with low testosterone and type 2 diabetes who started semaglutide increased total testosterone by an average of 1.6 nmol/L. The likely mechanism is straightforward — less fat tissue means less aromatase activity converting testosterone away.
It's not a one-way street, though. A separate medical records analysis found that non-diabetic men using semaglutide were slightly more likely to develop low testosterone than non-users — a reminder that this relationship is still being actively studied and doesn't resolve the same way for every patient.
Is it safe to take both at the same time?
Clinical guidance to date has not identified a major pharmacokinetic drug interaction between GLP-1 receptor agonists (semaglutide, tirzepatide) and testosterone, whether injected, gel, or oral. Weekly testosterone injections and weekly GLP-1 injections can be given the same day or different days with standard injection-site rotation for each — there's no pharmacological reason to separate them.
What does change is the dosing math. As GLP-1-driven weight loss reduces aromatase activity, endogenous testosterone production can rise on its own — which means a TRT dose that was correct at your starting weight may become too high after significant fat loss. That's the reason ongoing monitoring matters more here than it would with either treatment alone.
What monitoring should actually look like
- Baseline hormone panel before starting either therapy if you haven't already — testosterone, estradiol, and hematocrit
- Testosterone and hematocrit rechecked every 3–6 months, more frequently during periods of rapid weight loss
- Lipid panel and fasting glucose monitoring, since both therapies interact with metabolic markers independently
- Flagging significant weight milestones to your prescriber — typically every 15–20 pounds lost — since that's when dose adjustment becomes more likely
A detail worth confirming with any platform
Most online-TRT-only clinics don't coordinate GLP-1 management, and most GLP-1-only platforms don't manage testosterone. If you want both, confirm the platform actually integrates the two rather than treating them as separate, uncoordinated prescriptions from providers who aren't looking at your full picture.
Who shouldn't combine them
Men with normal testosterone levels. This combination isn't recommended for weight loss alone in men without diagnosed low testosterone — TRT in that context isn't addressing a deficiency.
A history of pancreatitis, medullary thyroid cancer, or MEN2 syndrome. These are contraindications for GLP-1 therapy independent of the TRT question.
A heart attack or stroke within the past six months. Both therapies typically require this window to pass before starting.
Disclose every medication to every prescriber. Don't assume the provider managing your TRT has seen your GLP-1 labs, or vice versa.
A regulatory note worth knowing
Online testosterone prescribing without a prior in-person visit currently relies on the same temporary DEA telemedicine flexibility covering other controlled substances — a rule that's been extended repeatedly but isn't permanent. Separately, the FDA issued warning letters to more than 30 telehealth companies in March 2026 over misleading marketing of compounded GLP-1 products, the largest coordinated enforcement action the industry has faced since the compounding boom began. Both are reasons to choose a platform with a track record, not just a low price.
Providers offering coordinated care
The provider below includes both TRT and GLP-1 options within reach of the same broader network.
Platforms offering both verticals
Feel30's TRT program includes baseline and follow-up labs as part of its standard protocol, a reasonable foundation if you're also planning to add GLP-1 therapy.
See Feel30's TRT program → Paid linkWellorithm's compounded GLP-1 options include both oral and injectable formats, useful if you're coordinating dosing schedules with a separate TRT provider.
See Wellorithm's program → Paid linkThe bottom line
The biology behind combining TRT and GLP-1 therapy is genuinely sound for the right patient — a man with confirmed low testosterone and significant excess weight, not someone chasing an edge with normal labs. What makes it safe is the same thing that makes any long-term treatment safe: real monitoring, honest disclosure to every provider involved, and a platform actually built to coordinate the two rather than treat them as separate transactions.